Impact of Intrapatient Immunosuppression Variability in Liver Transplantation Outcomes: A Systematic Review and...

Area of Science:

• Transplantation Medicine
• Pharmacology
• Clinical Outcomes Research

Background:

• Liver transplantation requires lifelong immunosuppression.
• Intrapatient variability (IPV) in drug levels is common.
• The impact of IPV on post-transplant outcomes requires further clarification.

Purpose of the Study:

• To investigate the association between intrapatient variability (IPV) in immunosuppressant drug levels and key health outcomes in liver transplant recipients.
• To synthesize existing evidence on the relationship between drug level variability and post-transplant complications.

Main Methods:

• A systematic review and meta-analysis of relevant literature.
• Searched major databases including MEDLINE/PubMed, Embase, Web of Science, Cochrane Reviews, and Cochrane CENTRAL.
• Included studies reporting on acute rejection, graft survival, acute kidney injury, and cancer risk.

Main Results:

• Lower IPV was associated with a 19% reduced risk of acute rejection (RR = 0.81).
• High IPV showed a consistent association with acute kidney injury across multiple studies.
• Evidence for graft survival and cancer risk (hepatocellular carcinoma) was inconsistent or limited.

Conclusions:

• A statistically significant, albeit marginal, association exists between high IPV and increased acute rejection risk.
• Optimizing immunosuppressant drug level management is vital for improving outcomes in liver transplant patients.
• Further research is needed to fully elucidate the impact of IPV on diverse post-transplant health outcomes.